Population-based estimates of breast cancer risks associated with ATM gene variants c.7271T > G and c.1066-6T > G (IVS10-6T > G) from the breast cancer family registry

Human Mutation

Volumn 27, Issue 11, 2006, Pages 1122-1128

  Bernstein, J L ^a   Teraoka, S ^b   Southey, M C ^c,d   Jenkins, M A ^c   Andrulis, I L ^e   Knight, J A ^e   John, E M ^f   Lapinski, R ^g   Wolitzer, A L ^a   Whittemore, A S ^h   West, D ^f   Seminara, D ⁱ   Olson, E R ^b   Spurdle, A B ^j   Chenevix Trench, G ^j   Giles, G G ^c,k   Hopper, J L ^c   Concannon, P ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b BENAROYA RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^e MOUNT SINAI HOSPITAL   (Canada)

^f NORTHERN CALIFORNIA CANCER CENTER   (United States)

^g MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^h STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ NATIONAL CANCER INSTITUTE   (United States)

^j QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^k CANCER EPIDEMIOLOGY CENTRE   (Australia)

more..

Author keywords

ATM gene variants; Breast cancer; DNA damage; Penetrance; Segregation analysis

Indexed keywords

ADULT; ALLELE; ARTICLE; ATAXIA TELANGIECTASIA; ATM GENE; BREAST CANCER; CANCER INCIDENCE; CANCER REGISTRY; CANCER RISK; CONTROLLED STUDY; FEMALE; GENE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN FUNCTION;

ADOLESCENT; ADULT; AGED; AUSTRALIA; BREAST NEOPLASMS; CARCINOMA; CASE-CONTROL STUDIES; CELL CYCLE PROTEINS; DNA-BINDING PROTEINS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETICS, POPULATION; HUMANS; INCIDENCE; LINKAGE (GENETICS); MIDDLE AGED; ONTARIO; PROTEIN-SERINE-THREONINE KINASES; REGISTRIES; RISK FACTORS; SAN FRANCISCO; TUMOR SUPPRESSOR PROTEINS; VARIATION (GENETICS);

ATAXIA TELANGIECTASIA;

EID: 33750904243     PISSN: 10597794     EISSN: None     Source Type: Journal    
DOI: 10.1002/humu.20415     Document Type: Article

References (41)

1. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tulinius H, Thorlacius S, Eerola H, Nevanlinna H, Syrjakoski K, Kallioniemi OP, Thompson D, Evans C, Peto J, Lalloo F, Evans DG, Easton DF. 2003. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72:1117-1130.
2. Athma P, Rappaport R, Swift M. 1996. Molecular genotyping shows that ataxia-telangiectasia heterozygotes are predisposed to breast cancer. Cancer Genet Cytogenet 92:130-134.
3. Bakkenist CJ, Kastan MB. 2003. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 421:499-506.
4. Bakkenist CJ, Kastan MB. 2004. Initiating cellular stress responses. Cell 118:9-17.
5. Bebb DG, Yu Z, Chen J, Telatar M, Gelmon K, Phillips N, Gatti RA, Glickman BW. 1999. Absence of mutations in the ATM gene in forty-seven cases of sporadic breast cancer. Br J Cancer 80:1979-1981.
6. Bernstein JL, Bernstein L, Thompson WD, Lynch CF, Malone KE, Teitelbaum SL, Olsen JH, Anton-Culver H, Boice JD, Rosenstein BS, Borresen-Dale AL, Gatti RA, Concannon P, Haile RW. 2003a. ATM variants 7271T > G and IVS10-6T > G among women with unilateral and bilateral breast cancer. Br J Cancer 89:1513-1516.
7. Bernstein JL, Teraoka S, Haile RW, Borresen-Dale AL, Rosenstein BS, Gatti RA, Diep AT, Jansen L, Atencio DP, Olsen JH, Bernstein L, Teitelbaum SL, Thompson WD, Concannon P. 2003b. Designing and implementing quality control for multi-center screening of mutations in the ATM gene among women with breast cancer. Hum Mutat 21:542-550.
8. Bishop D, Hopper J. 1997. AT-tributable risks? Nat Genet 15:226.
9. Borresen A, Andersen T, Tretli S, Heilberg A, Moller P. 1990. Breast cancer and other cancers in Norwegian families with ataxia-telangiectasia. Genes Chromosomes Cancer 2:339-340.
10. Broeks A, Urbanus JH, Floore AN, Dahler EC, Klijn JG, Rutgers EJ, Devilee P, Russell NS, van Leeuwen FE, 't Veer LJ. 2000. ATM-heterozygous germline mutations contribute to breast cancer-susceptibility. Am J Hum Genet 66:494-500.
11. Buchholz TA, Weil MM, Ashorn CL, Strom EA, Sigurdson A, Bondy M, Chakraborty R, Cox JD, McNeese MD, Story MD. 2004. A Ser49Cys variant in the ataxia telangiectasia, mutated, gene that is more common in patients with breast carcinoma compared with population controls. Cancer 100:1345-1351.
12. Cavaciuti E, Lauge A, Janin N, Ossian K, Hall J, Stoppa-Lyonnet D, Andrieu N. 2005. Cancer risk according to type and location of ATM mutation in ataxia-telangiectasia families. Genes Chromosomes Cancer 42:1-9.
13. Chenevix-Trench G, Spurdle AB, Gatei M, Kelly H, Marsh A, Chen X, Donn K, Cummings M, Nyholt D, Jenkins MA, Scott C, Pupo GM, Dork T, Bendix R, Kirk J, Tucker K, McCredie MR, Hopper JL, Sambrook J, Mann GJ, Khanna KK. 2002. Dominant negative ATM mutations in breast cancer families. J Natl Cancer Inst 94:205-215.
14. Dork T, Bendix R, Bremer M, Rades D, Klopper K, Nicke M, Skawran B, Hector A, Yamini P, Steinmann D, Weise S, Stuhrmann M, Karstens JH. 2001. Spectrum of ATM gene mutations in a hospital-based series of unselected breast cancer patients. Cancer Res 61:7608-7615.
15. FitzGerald MG, Bean JM, Hegde SR, Unsal H, MacDonald DJ, Harkin DP, Finkelstein DM, Isselbacher KJ, Haber DA. 1997. Heterozygous ATM mutations do not contribute to early onset of breast cancer. Nat Genet 15:307-310.
16. Gatti RA, Tward A, Concannon P. 1999. Cancer risk in ATM heterozygotes: a model of phenotypic and mechanistic differences between missense and truncating mutations. Mol Genet Metab 68:419-423.
17. Geoffroy-Perez B, Janin N, Ossian K, Lauge A, Croquette MF, Griscelli C, Debre M, Bressac-de-Paillerets B, Aurias A, Stoppa-Lyonnet D, Andrieu N. 2001. Cancer risk in heterozygotes for ataxia-telangiectasia. Int J Cancer 93:288-293.
18. Gutierrez-Enriquez S, Fernet M, Dork T, Bremer M, Lauge A, Stoppa-Lyonnet D, Moullan N, Angele S, Hall J. 2004. Functional consequences of ATM sequence variants for chromosomal radiosensitivity. Genes Chromosomes Cancer 40:109-119.
19. Halbert H. 1980. A heteroskedasticity-consistent covariance matrix estimator and a direct test for heteroskedasticity. Econometrica 48:817-838.
20. Hopper JL, Southey MC, Dite GS, Jolley DJ, Giles GG, McCredie MR, Easton DF, Venter DJ. 1999. Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study. Cancer Epidemiol Biomarkers Prev 8:741-747.
21. Inskip H, Kinlen L, Taylor A, Woods C, Arlett C. 1999. Risk of breast cancer and other cancers in heterozygotes for ataxia telangiectasia. Br J Cancer 79:1304-1307.
22. Izatt L, Greenman J, Hodgson S, Ellis D, Watts S, Scott G, Jacobs C, Liebmann R, Zvelebil MJ, Mathew C, Solomon E. 1999. Identification of germline missense mutations and rare allelic variants in the ATM gene in early-onset breast cancer. Genes Chromosomes Cancer 26:286-294.
23. Janin N, Andrieu N, Ossaian K, Lauge A, Croquette M, Griscelli C, Debre M, Bressac-de-Paillertes B, Aurias A, Stoppa-Lyonnet D. 1999. Breast cancer risk in ataxia telangiectasia (AT) heterozygotes: haplotype study in French AT families. Br J Cancer 80:1042-1045.
24. John EM, Hopper JL, Beck JC, Knight JA, Neuhausen SL, Senie RT, Ziogas A, Andrulis IL, Anton-Culver H, Boyd N, Buys SS, Daly MB, O'Malley FP, Santella RM, Southey MC, Venne VL, Venter DJ, West DW, Whittemore AS, Seminara D. 2004. The Breast Cancer Family Registry: an infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancer. Breast Cancer Res 6:R375-R389.
25. Kurz EU, Lees-Miller SP. 2004. DNA damage-induced activation of ATM and ATM-dependent signaling pathways. DNA Repair (Amst) 3:889-900.
26. Lange K, Weeks D, Boehnke M. 1988. Programs for pedigree analysis: MENDEL, FISHER, and dGENE. Genet Epidemiol 5:471-472.
27. Ng PC, Henikoff S. 2002. Accounting for human polymorphisms predicted to affect protein function. Genome Res 12:436-446.
28. Olsen JH, Hahnemann JM, Borresen-Dale AL, Brondum-Nielsen K, Hammarstrom L, Kleinerman R, Kaariainen H, Lonnqvist T, Sankila R, Seersholm N, Tretli S, Yuen J, Boice JD Jr, Tucker M. 2001. Cancer in patients with ataxia-telangiectasia and in their relatives in the Nordic countries. J Natl Cancer Inst 93:121-127.
29. Piegorsch W, Weinberg C, Taylor J. 1994. Non-hierarchical logistic models and case-only designs for assessing susceptibility in population-based case-control studies. Stat Med 13:153-162.
30. Savitsky K, Bar-Shira A, Gilad S, Rotman G, Ziv Y, Vanagaite L, Tagle DA, Smith S, Uziel T, Sfez S, Ashkenazi M, Pecker I, Frydman M, Harnik R, Patanjali SR, Simmons A, Clines GA, Sartiel A, Gatti RA, Chessa L, Sanal O, Lavin MF, Jaspers NGJ, Taylor MR, Arlett CF, Miki T, Weissman SM, Lovett M, Collins FS, Shiloh Y. 1995. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science 268:1749-1753.
31. Scott SP, Bendix R, Chen P, Clark R, Dork T Lavin MF. 2002. Missense mutations but not allelic variants alter the function of ATM by dominant interference in patients with breast cancer. Proc Natl Acad Sci USA 99:925-930.
32. Sommer SS, Buzin CH, Jung M, Zheng J, Liu Q, Jeong SJ, Moulds J, Nguyen VQ, Feng JN, Bennett WP, Dritschilo A. 2002. Elevated frequency of ATM gene missense mutations in breast cancer relative to ethnically matched controls. Cancer Genet Cytogenet 134:25-32.
33. Stankovic T, Kidd A, Sutcliffe A, McGuire G, Robinson P, Weber P, Bedenham T, Bradwell A, Easton D, Lennox G, Haites N, Byrd P, Taylor A. 1998. ATM mutations and phenotypes in ataxia-telangiectasia families in the British Isles: expression of mutant ATM and the risk of leukemia, lymphoma, and breast cancer. Am J Hum Genet 62:334-345.
34. Sunyaev S, Ramensky V, Koch I, Lathe W, III, Kondrashov AS, Bork P. 2001. Prediction of deleterious human alleles. Hum Mol Genet 10:591-597.
35. Swift M, Reitnauer P, Morrell D, Chase C. 1987. Breast and other cancers in families with ataxia-telangiectasia. N Engl J Med 316:1289-1294.
36. Swift M, Morrell D, Massey R, Chase C. 1991. Incidence of cancer in 161 families affected by ataxia-telangiectasia. N Engl J Med 325:1831-1836.
37. Szabo CI, Schutte M, Broeks A, Houwing-Duistermaat JJ, Thorstenson YR, Durocher F, Oldenburg RA, Wasielewski M, Odefrey F, Thompson D, Floore AN, Kraan J, Klijn JG, van den Ouweland AM, Wagner TM, Devilee P, Simard J, 't Veer LJ, Goldgar DE, Meijers-Heijboer H. 2004. Are ATM mutations 7271T→G and IVS10-6T→G really high-risk breast cancer-susceptibility alleles? Cancer Res 64:840-843.
38. Tamimi RM, Hankinson SE, Spiegelman D, Kraft P, Colditz GA, Hunter DJ. 2004. Common ataxia telangiectasia mutated haplotypes and risk of breast cancer: a nested case-control study. Breast Cancer Res 6: R416-R422.
39. Teraoka SN, Malone KE, Doody DR, Suter NM, Ostrander EA, Daling JR, Concannon P. 2001. Increased frequency of ATM mutations in breast carcinoma patients with early onset disease and positive family history. Cancer 92:479-487.
40. Thompson D, Antoniou AC, Jenkins M, Marsh A, Chen X, Wayne T, Tesoriero A, Milne R, Spurdle A, Thorstenson Y, Southey M, Giles GG, Khanna KK, Sambrook J, Oefner P, Goldgar D, Hopper JL, Easton D, Chenevix-Trench G. 2005a. Two ATM variants and breast cancer risk. Hum Mutat 25:594-595.
41. Thompson D, Duedal S, Kirner J, McGuffog L, Last J, Reiman A, Byrd P, Taylor M, Easton DF. 2005b. Cancer risks and mortality in heterozygous ATM mutation carriers. J Natl Cancer Inst 97:813-822.